For children who cannot swallow tablets, an oral suspension may be substituted as described below: Preparation of Oral Suspension: Candesartan cilexetil oral suspension can be prepared in concentrations within the range of 0. If blood pressure is not controlled by candesartan cilexetil tablets alone, a diuretic may be added. While no specific drug interactions have been identified with systemic agents and apraclonidine during clinical trials, it is theoretically possible that additive blood pressure reductions could occur when apraclonidine is combined with the use of antihypertensive agents.Next
Coadministration may result in elevated candesartan plasma concentrations.
The authors concluded that the presence of hypertension likely contributed to the development of birth defects rather than the use of medications. In addition, angiotensin II receptor antagonists have been associated with a reduced incidence in the development of new-onset diabetes in patients with hypertension or other cardiac disease. However, in clinical trials with alprostadil intracavernous injection, anti-hypertensive agents had no apparent effect on the safety and efficacy of alprostadil.Next
The authors noted that there was a higher risk of major birth defects with ARB therapy beyond 6 weeks of gestation compared to discontinuation of ARBs before week 6, 7.
In the ALTITUDE trial, patients with type 2 diabetes and renal impairment, a population at high risk for cardiovascular and renal events, were given aliskiren in addition to ACE inhibitors or ARBs. Closely monitor blood pressure, renal function, and electrolytes if aliskiren must be combined with another RAAS inhibitor.Next
Metformin; Rosiglitazone: Moderate Angiotensin II receptor antagonists ARBs may enhance the hypoglycemic effects of metformin by improving insulin sensitivity.
The recommended starting dose is 8 to 16 mg. Patients receiving these drugs together should be monitored for changes in renal function and glycemic control. Tezacaftor; Ivacaftor: Minor Increased monitoring is recommended if ivacaftor is administered concurrently with CYP2C9 substrates, such as candesartan.Next
Data sources include the U.
Blood pressure and heart rates should be monitored closely to confirm that the desired antihypertensive effect is achieved. In vitro studies showed ivacaftor to be a weak inhibitor of CYP2C9.
Use in Hepatic Impairment: Initiate with 8 mg candesartan cilexetil tablets in patients with moderate hepatic insufficiency.
If blood pressure is not controlled by candesartan cilexetil alone, a diuretic may be added.Next
Monitor heart rate and blood pressure.
Do not use after the expiry date stated on the bottle.
Phenelzine: Moderate Additive hypotensive effects may be seen when phenelzine is combined with angiotensin II receptor antagonists.
ARBs may rarely reduce renal function, a risk factor for reduced renal clearance of metformin.Next
Monitor blood pressure regularly during use of this combination.